Tim Van Hauwermeiren, argenx CEO

Ar­genx wins sec­ond FDA ap­proval for Vyv­gart in au­toim­mune nerve dis­ease

Af­ter a string of clin­i­cal fail­ures, the Dutch biotech ar­genx land­ed a much-need­ed win on Fri­day when the FDA ap­proved its au­toim­mune dis­ease drug, Vyv­gart …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.